Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Promotional Assessments Reorganized Around Specialty, Not Target Audience

This article was originally published in The Pink Sheet Daily

Executive Summary

The two divisions within the Office of Prescription Drug Promotion are renamed the divisions of advertising and promotion review I and II; they will each have four teams operating within them in a structure akin to the Office of New Drugs.

Advertisement

Related Content

FDA Off-Label Citations Disappear In Post-Caronia Enforcement Letters
DTC Pre-review Requirement Broadly Defined Under FDA Draft Guidance
FDA's Drug Advertising Oversight Gets A Promotion From A Division To An Office

Topics

Advertisement
UsernamePublicRestriction

Register

PS075496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel